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Comorbidities of epilepsy: current concepts and future 
perspectives
Mark R Keezer, Sanjay M Sisodiya, Josemir W Sander
The burden of comorbidity in people with epilepsy is high. Several diseases, including depression, anxiety, dementia, 
migraine, heart disease, peptic ulcers, and arthritis are up to eight times more common in people with epilepsy than 
in the general population. Several mechanisms explain how epilepsy and comorbidities are associated, including 
shared risk factors and bidirectional relations. There is a pressing need for new and validated screening instruments 
and guidelines to help with the early detection and treatment of comorbid conditions. Preliminary evidence suggests 
that some conditions, such as depression and migraine, negatively aﬀ ect seizure outcome and quality of life. Further 
investigation is needed to explore these relations and the eﬀ ects of targeted interventions. Future advances in the 
investigation of the comorbidities of epilepsy will strengthen our understanding of epilepsy and could play an 
important part in stratiﬁ cation for genetic studies.
Introduction
Young adults have a median of two chronic health 
conditions, rising to six in people older than 65 years.1 
These ﬁ ndings have led some researchers to refer to the 
co-occurrence of several medical conditions in the same 
individual as a normal state of aﬀ airs.2 A comorbid 
condition (or comorbidity) is one that occurs during the 
course of an index disease (eg, epilepsy). Comorbidities 
are generally deﬁ ned in broad terms, including distinct 
clinical diseases and syndromes, and signs or symptoms 
of the index disease.1
Roughly 50% of adults with active epilepsy have at least 
one comorbid medical disorder.1,2 Several large 
population-based studies report various conditions that 
are up to eight times more prevalent in people with 
epilepsy relative to the general population.3,4 Appreciation 
of the relevance of these comorbidities is increasing 
because they aﬀ ect epilepsy prognosis and quality of life. 
For example, migraine and psychiatric comorbidities are 
associated with poor seizure outcome, whereas 
depression has been linked with reduced quality of life.5,6 
Despite this growing appreciation, few data are available 
on the most eﬀ ective methods to screen for comorbidities 
and the eﬀ ect of interventions on prognosis.
Here, we describe ideas relevant to the investigation 
and conceptualisation of the comorbidities of epilepsy. 
We review the present state of knowledge of comorbidities 
associated with epilepsy and explore the ways in which 
research into comorbidities aﬀ ords new opportunities 
for improvement in clinical care and scientiﬁ c discovery.
Measuring comorbidity
A fundamental step in the study of the comorbidities of 
epilepsy is to understand the ways in which comorbidities 
are measured. An important measure of comorbidity 
burden is prevalence, which is generally understood to 
represent point prevalence—the proportion of 
individuals at risk with the condition in question at a 
single point in time.7 When discussing the comorbidities 
of epilepsy, the emphasis is on whether the prevalence of 
comorbid conditions in those with epilepsy is diﬀ erent 
from that of the general population.8 This assessment 
can be done by comparing prevalence estimates (eg, 
using 95% CIs or p values) or by reporting prevalence 
ratios. Additional factors, such as sex or age, could have a 
strong eﬀ ect on the relative prevalence of two conditions. 
Adjusted prevalence ratios are an important method to 
control for such factors and can be calculated using 
straightforward statistical methods (appendix).9,10
Whereas prevalence estimates are used to measure the 
burden of a single condition, comorbidity indices are 
useful instruments to measure the overall comorbidity 
burden of an individual. The Charlson11 and the 
Elixhauser12,13 are the most commonly used indices, 
initially developed for use in observational studies to 
control for the potentially confounding eﬀ ect of 
comorbidity burden on in-hospital mortality, length of 
hospital stay, and hospitalisation cost. These indices 
assign points to particular comorbid conditions when 
present, the sum of which is a weighted score designed 
to predict prognosis. The Charlson index assigns between 
1 and 6 points for 19 diﬀ erent comorbid conditions, 
whereas the Elixhauser comorbidity measure assigns 
between −7 and 12 points for 21 conditions. These indices 
have been well validated in various populations,14 but 
have only recently been validated in people with epilepsy.
An epilepsy-speciﬁ c comorbidity index (ESI) was 
developed using a population-based administrative 
database of 7253 individuals with epilepsy in Calgary 
(AB, Canada).15 The ESI includes 14 conditions 
(pulmonary circulation disorders, hypertension, cardiac 
arrhythmias, congestive heart failure, peripheral vascular 
disease, renal disease, solid tumour without metastases, 
paraplegia and hemiplegia, aspiration pneumonia, 
dementia, brain tumour, anoxic brain injury, moderate or 
severe liver disease, and metastatic cancer), each assigned 
1–6 prognostic points. The total ESI score proved to 
be discriminating, with crude mortality ranging from 
4∙7 deaths per 1000 person-years for an ESI score of 0, to 
535∙6 deaths per 1000 person-years for a score greater 
than 10. The ESI has been validated and performed well 
in prospective longitudinal cohorts.16
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Mechanisms of association
Straightforward measurement of associations between 
diﬀ erent diseases has been referred to as an “empirical 
statistical phenomenon that has no meaning in itself”.17 
Measurement of associations is only the ﬁ rst step in a 
process in which an additional goal is to understand 
why speciﬁ c conditions are associated, which in turn 
might change our understanding of epilepsy and its 
clinical care.
Several models have been generated to account for 
the relation between comorbid disorders.17–19 Such 
models are not mutually exclusive and the same 
comorbid condition could have many reasons for being 
associated with epilepsy, even in the same individual. 
Intellectual disability might occur in people with 
tuberous sclerosis, for example, as a result of the 
underlying hamartomas or hamartia and as a result of 
the epileptic seizures (eg, in the context of West 
syndrome).20,21
A classiﬁ cation scheme for the diﬀ erent mechanisms of 
association between epilepsy and comorbid conditions 
has been presented previously.3 Here, we build on this 
initial scheme and incorporate additional aspects, 
dividing the mechanisms of association into ﬁ ve 
categories: chance and artifactual comorbidities, causative 
mechanisms, resultant mechanisms, shared risk factors, 
and bidirectional eﬀ ects (ﬁ gure 1).
Chance and artifactual comorbidities
Chance refers to a circumstance in which the prevalence 
or incidence of a condition is as frequent in people with 
epilepsy as would be expected in the general population. 
Artifactual comorbidity is any non-causal association 
between epilepsy and a comorbid condition that arises as 
a result of bias rather than a true causal relation. 
Artifactual comorbidity can be divided into two major 
forms: information bias and selection bias.
Information bias is deﬁ ned as any systematic (ie, non-
random) error in the data collected that leads to results 
that are diﬀ erent from the reality.22 An apparent rise in 
the prevalence of a comorbid condition that is only as a 
result of inaccuracies in the identiﬁ cation of those with 
epilepsy or the comorbid condition is an example of 
information bias. Important subtypes of information 
bias are recall bias (eg, individuals with epilepsy are more 
likely to recall a past history of mild head trauma than 
those without epilepsy) and surveillance bias (eg, 
individuals with epilepsy are more likely to be closely 
monitored for other diseases).23,24
Selection bias, the second form of artifactual 
comorbidity, occurs when the study population does not 
accurately represent those individuals initially eligible for 
inclusion in such a way that systematically alters the 
relation between conditions.22,25 Several types of selection 
bias are relevant to the investigation of the comorbidities 
of epilepsy. Referral bias can occur when participants are 
recruited from a specialised medical setting, in which 
only people with severe disease are studied, rather than 
the general population.23 Non-response bias arises when 
particular factors aﬀ ect some individuals’ decisions to 
participate in a study.25 Publication bias is a form of 
selection bias that is at the level of the overall study rather 
than the participants, which happens when speciﬁ c data 
are not reported, as a result of bias on the part of authors, 
editors, or peer reviewers.23,25
Causative mechanisms
Causative mechanisms are one of the simplest 
mechanisms of association. Here, the comorbid condition 
arises ﬁ rst, which then gives rise to epilepsy via direct or 
indirect causal mechanisms. Cerebrovascular disease, for 
example, directly causes about 10% of incident 
epilepsies,26 whereas cigarette smoking can indirectly 
cause epilepsy as a result of neoplasm or stroke.
Resultant mechanisms
The resultant mechanism of association is similar to the 
causative model, but the temporal sequence is reversed—
ie, epilepsy takes place ﬁ rst and subsequently gives rise 
to the comorbid condition. Aspiration pneumonia or 
seizure-related skeletal fractures are examples of 
resultant comorbidities of epilepsy. The resultant relation 
is probably an indirect association caused by the eﬀ ects 
of seizures or the associated treatments, although this is 
yet to be proven.
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Figure 1: Mechanisms of association between epilepsy and its comorbidities
Each arrow with a solid line represents a casual association, with the cause leading to the eﬀ ect. Arrows with 
dashed lines represent non-causal associations.
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Shared risk factors
Unlike the causative and resultant models, the shared 
risk factor mechanism of association is not indicative of a 
causal relation between epilepsy and its comorbidity. 
This model, in fact, describes a spurious (ie, biased) 
association as a result of a confounding factor, in which 
the confounder is deﬁ ned as a common cause for 
epilepsy and the comorbid condition.27 Unlike the other 
biased associations as seen in artifactual comorbidity, 
however, the causal relation between epilepsy, the 
comorbidity, and the shared risk factor is genuine 
(ﬁ gure 1) and its investigation represents both a clinical 
imperative and a research opportunity. Shared risk 
factors can be genetic, environmental, structural, or 
physiological.3 Perinatal hypoxaemic brain injury, for 
example, could result in epilepsy and comorbid spastic 
paraparesis.
Bidirectional eﬀ ects
Bidirectional eﬀ ects, also known as reciprocal eﬀ ects, 
arise when two conditions can each cause the other.7 
Establishing that the temporal sequence is reciprocal (ie, 
that either could precede the other) is insuﬃ  cient to 
prove bidirectionality. Variability in the temporal 
sequence of epilepsy and a comorbid condition could 
similarly occur in the context of the shared risk factor 
model. Some investigators have argued that there is a 
bidirectional relation between autism spectrum disorder 
(ASD) and epilepsy.28 In the context of tuberous sclerosis, 
for example, this association is unlikely to be a 
bidirectional eﬀ ect; but rather, in some individuals, the 
ASD might be identiﬁ ed before the onset of epilepsy and 
in others the reverse is true. This example is evidence of 
the potentially complex interaction between genetics, 
structural pathological changes, and environment, rather 
than evidence that ASD can cause epilepsy and vice 
versa. In other words, an important distinction exists 
between bidirectional causality and varying temporal 
sequence between individuals.
The role of genetics
The interplay between genetics, epilepsy, and its 
comorbidities is of interest and warrants particular 
attention. The various ways in which genetic factors relate 
to the comorbidities of epilepsy are summarised in 
ﬁ gure 2. Perhaps most evident is the way in which genetic 
mutations might act as shared risk factors—eg, SCN1A 
mutations predispose individuals to the development of 
epilepsy and a gait disorder.29 Such mutations are 
examples of genetic pleiotropy, in which the same genes 
can aﬀ ect several diﬀ erent traits or disorders.30
The interaction between genetics, epilepsy, and its 
comorbidities extends beyond genetic pleiotropy, 
however, and could include causative or resultant 
associations,30 in which a genetic factor gives rise to 
condition A, which in turn causes condition B. A 
mutation of the TSC1 gene in tuberous sclerosis, for 
example, directly results in cortical tubers, some of which 
(along with surrounding cortical tissue) might result in 
epilepsy via a causative association.31
Genetic factors can also act as modiﬁ ers, acting as a 
third variable that aﬀ ects the relation between a cause 
and eﬀ ect—eg, epilepsy and a comorbidity.32 Examples of 
such relations are the increased risk of epilepsy after 
traumatic brain injury in carriers of the APOE4 allele,33 
and the heightened risk of Stevens-Johnson syndrome 
after the initiation of carbamazepine in carriers of the 
HLAB*150234 or HLA-A*310135 alleles.
The burden of comorbidity
Several large and comprehensive studies have examined 
the comorbidity burden in people with epilepsy, and we 
now describe this research and the relevance of such 
comorbidities in the context of the concepts underpinning 
comorbidity research discussed above. These large 
studies have used population-based cohorts and 
administrative databases in the UK,36 Canada,37,38 and the 
USA,39–43 and have consistently shown a higher prevalence 
of several somatic and psychiatric conditions in people 
with epilepsy than in those without epilepsy (table).
Many of the associations between epilepsy and the 
listed comorbid conditions are not surprising in view of 
their known roles as causes of epilepsy (eg, CNS 
neoplasm, stroke, and Alzheimer’s disease).44 
Arrhythmias might occur as a result of the eﬀ ect of 
antiepileptic drugs.37 Shared risk factors could account 
for the relation between epilepsy and heart disease (ie, 
shared vascular risk factors that lead to stroke) or 
migraine (ie, excessive cortical hyperexcitability).41,45 The 
association between epilepsy and diabetes seems to be 
especially true for type 1 diabetes and might be related to 
the shared presence of anti-glutamic acid decarboxylase 
(GAD) antibodies, which are strongly associated with 
type 1 diabetes (in about 80% of individuals) and are 
present in up to 6% of people with epilepsy.46 Allergies 
have been suggested to be the eﬀ ect of speciﬁ c 
antiepileptic drugs in some people, and asthma might 
Figure 2: The relation between genetics, epilepsy, and its comorbidities
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occur as a result of associated environmental and living 
conditions that might be indirectly related to epilepsy.3 
The burden of comorbidities in people with epilepsy is 
higher, but their distribution seems to be similar to that 
in the general population, with more prevalent 
migraine, asthma, and brain neoplasms in individuals 
BRFSS (Kobau 
et al41)
CHIS (Elliott 
et al42)
CHS 2005
(Téllez-Zenteno 
et al37)
CHS 2007
(Téllez-Zenteno 
et al38)
EPIC (Ottman 
et al39)
GPRD (Gaitatzis 
et al36)
NHIS 2002 
(Strine et al40)
NHIS 2010 
(Kadima 
et al43)
NPHS 
(Téllez-Zenteno 
et al37)
Source of data (study country) Telephone 
survey (USA)
Telephone 
survey (USA)
Door-to-door 
survey (Canada)
Door-to-door 
survey (Canada)
Postal survey 
(USA)
GP recorded 
diagnoses (UK)
Survey with 
face-to-face 
interviews 
(USA)
Survey with 
face-to-face 
interviews 
(USA)
Door-to-door 
survey (Canada)
Reported prevalence % (95% CI) in 
people with 
active epilepsy 
vs people 
without 
epilepsy
% (95% CI) in 
people with vs 
people without 
epilepsy
PR (95% CI) % (95% CI) in 
people with vs 
people without 
epilepsy
PR (95% CI) PR (95% CI) Adjusted† PR  
(95% CI)
% (95% CI) in 
people with vs 
people 
without 
epilepsy
PR (95% CI)
ICD chapter II: neoplasm
Neoplasm (unspeciﬁ ed) .. 11·1%
(8·4–14·4) vs 
7·9% (7·6–8·1)
1·4
(0·9–2·1)
.. .. .. 2·4
(1·7–3·4)
11·3%
(8·6–14·9) vs 
8·1% (7·7–8·5)
1·2
(0·7–2·1)
ICD chapter IV: endocrine, nutritional, and metabolic diseases
Diabetes mellitus 
(unspeciﬁ ed)
13·0%
(8·3–19·7) vs 
7·7% (7·4–8·0)
7·7%
(5·4–10·9) vs 
5·7% (5·4–6·0)‡
1·2
(0·9–1·6)
.. 1·0
(0·9–1·1)
1·6
(1·4–1·8)
1·3
(0·9–1·9)
10·4%
(7·7–14·0) vs 
8·7% (8·2–9·1)
1·6
(1·2–2·0)
Thyroid condition .. .. 1·6
(1·3–2·1)
.. .. .. .. .. 1·3
(0·9–1·7)
ICD chapter V: mental and behavioural disorders
Major depression .. .. .. 17·4%
(10·0–24·9) vs 
10·7% 
(10·2–11·2)
1·3
(1·2–1·4)
2·0
(1·9–2·1)
.. .. ..
Anxiety .. .. .. 22·8%
(14·8–30·9) vs 
11·2% 
(10·8–11·7)
1·6
(1·5–1·8)
2·0
(1·9–2·1)
.. .. ..
ICD chapter VI: nervous system
Dementia (unspeciﬁ ed) .. .. .. .. .. 6·3
(5·5–7·4)
.. .. 4·3
(2·7–7·4)
Alzheimer’s disease .. .. .. .. .. 8·1
(5·9–11·0)
.. .. ..
Migraine .. .. 2·0
(1·7–2·3)
.. 1·4
(1·3–1·5)
1·6
(1·4–1·8)
3·0
(2·3–3·8)§
34·7%
(30·1–39·5) vs 
16·2% 
(15·7–16·8)¶
2·6
(2·2–3·0)
ICD chapter VII: eye and adnexa
Glaucoma .. .. 1·2
(0·7–1·9)
.. .. .. .. .. 1·1
(0·6–1·9)
Cataracts .. .. 1·2
(0·9–1·6)
.. .. .. .. .. 2·4
(1·9–2·9)
ICD chapter IX: circulatory system
Stroke (unspeciﬁ ed) 15·7%
(11·3–21·4) vs 
2·4% (2·3–2·6)
9·4%
(6·9–12·8) vs 
2·2% (2·0–2·4)
3·9
(2·7–5·3)
.. .. 7·0
(6·4–7·6)
7·7
(5·1–11·7)
14·3%
(11·1–18·2) vs 
2·4% (2·2–2·7)
4·7
(3·4–6·2)
Heart disease (unspeciﬁ ed) 8·4%
(5·6–11·8) vs 
4·6% (4·3–4·8)
9·7%
(7·3–12·9) vs 
6·2% (5·9–6·5)
2·3
(1·9–2·7)
.. .. .. 2·5
(1·8–3·4)
18·3%
(14·7–22·6) vs 
11·3% 
(10·9–11·8)
1·8
(1·4–2·3)
Hypertension .. 28·8%
(23·8–34·3) vs 
24·8% 
(24·2–25·3)
1·1
(0·9–1·3)
.. 1·0
(0·9–1·1)
.. .. 34·2%
(29·7–39·0) vs 
29·0% 
(28·4–29·6)
1·9
(1·7–2·2)
(Table continues on next page)
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younger than 64 years and more prevalent 
cerebrovascular and cardiovascular disease, and 
meningioma in individuals older than 64 years.36
Many studies have consistently reported an increased 
burden of several comorbidities in people with epilepsy. 
The degree to which these associations between epilepsy 
and comorbid conditions result from artifactual 
comorbidity rather than true causal relations is uncertain. 
Many of the studies discussed above relied on unvalidated 
screening instruments to identify individuals with or 
without epilepsy and with or without comorbidities.36–38,40,42,43 
Of note, evidence suggests that if individuals with epilepsy 
are asked whether or not they have epilepsy, around a 
quarter of the group will say that they do not,47 which 
emphasises the importance of an accurate screening 
instrument. For conditions such as migraine or 
ﬁ bromyalgia, which are frequently under diagnosed48,49 
(especially in the case of mild disease), a higher prevalence 
in people with epilepsy than in those without epilepsy in 
these observational and retrospective studies could 
conceivably be as a result, at least in part, of recall or 
surveillance bias. The response rate was approximately 
50–60% in several studies,39,41,43 rising as high as 75–85% in 
others.37,38,40 Not surprisingly, investigations that relied on 
telephone or postal surveys had lower response rates, 
placing them at particular risk of non-response bias. To 
maximise accuracy, future studies should be 
population-based to produce ﬁ ndings that are more 
generalisable and at lower risk of referral bias, use 
prospective data collection to reduce the risk of recall bias, 
BRFSS (Kobau 
et al41)
CHIS (Elliott 
et al42)
CHS 2005
(Téllez-Zenteno 
et al37)
CHS 2007
(Téllez-Zenteno 
et al38)
EPIC (Ottman 
et al39)
GPRD (Gaitatzis 
et al36)
NHIS 2002 
(Strine et al40)
NHIS 2010 
(Kadima 
et al43)
NPHS 
(Téllez-Zenteno 
et al37)
(Continued from previous page)
ICD chapter X: respiratory system
COPD .. 5·2%
(3·6–7·6) vs 
1·9% (1·8–2·1)
2·9
(2·0–4·0)
.. .. .. .. .. 1·9
(1·3–2·5)
Chronic bronchitis .. .. .. .. .. 1·7
(1·3–2·2)
.. 7·5%
(5·2–10·6) vs 
4·1% (3·8–4·5)
..
Emphysema .. .. .. .. .. 1·3
(0·7–2·3)
.. 5·5%
(3·5–8·3) vs 
1·7% (1·5–2·0)
..
Asthma 20·3%
(15·3–26·4) vs 
8·2% (7·8–8·6)
21·9%
(18·2–26·2) vs 
12·6% 
(12·1–13·1)
1·4
(1·1–1·7)
.. 1·3
(1·1–1·4)
1·3
(1·2–1·4)
1·8
(1·4–2·4)
19·2%
(15·2–24·0) vs 
12·6% 
(12·0–13·2)
1·1
(0·8–1·3)
ICD chapter XI: digestive system
Peptic ulcers .. .. 2·5
(2·0–3·2)
.. .. 1·9
(1·6–2·4)
.. 12·4%
(9·2–16·5) vs 
6·2% (5·8–6·6)
2·7
(2·1–3·4)
Bowel disorders (Crohn’s 
and ulcerative colitis)
.. .. 2·0
(1·4–2·7)
.. .. .. .. .. 3·3
(2·4–4·3)
ICD chapter XIII: musculoskeletal system and connective tissues
Allergies .. .. 1·2
(1·0–1·3)
.. .. .. .. .. 1·6
(1·4–1·8)
Back problems .. .. 1·4
(1·2–1·6)
.. .. .. .. .. 1·5
(1·3–1·7)
Fibromyalgia .. .. 1·5
(0·9–2·4)
.. 2·0
(1·7–2·3)
.. .. .. ..
Arthritis (unspeciﬁ ed) 43·0%
(37·0–49·2) vs 
28·0% 
(27·5–28·6)
32·3%
(27·4–37·5) vs 
18·9% 
(18·5–19·3)
1·4
(1·2–1·6)
.. .. .. 2·3
(1·7–3·0)||
30·9%
(27·3–34·8) vs 
21·4% 
(20·8–22·0)
1·5
(1·3–1·7)
ICD chapter XIV: genitourinary system
Urinary incontinence .. .. 3·2
(2·4–4·1)
.. .. .. .. .. 4·4
(3·5–5·5)
BRFSS=Behavioural Risk Factor Surveillance System. CHIS=California Health Interview Survey. CHS=Community Health Survey. EPIC=Epilepsy Comorbidities and Health Survey. GPRD=General Practice Research 
Database. ICD=International Statistical Classiﬁ cation of Diseases and Related Health Problems. NHIS=National Health Interview Survey. NPHS=National Population Health Survey. GP=general practitioners. 
PR=prevalence ratio. OR=prevalence odds ratio. COPD=chronic obstructive pulmonary disease. *Lifetime prevalences are reported, unless otherwise indicated, for comorbidities by ICD-10 chapters; for practical 
reasons, the comorbidities listed are those that were recorded in at least two of the studies. †Adjusted for age, sex, race or ethnicity, education, marital, and employment status. ‡Limited to type 2 diabetes. 
§Deﬁ ned as a history of severe headache or migraine during the previous 3 months. ¶Includes a history of severe headaches. ||Includes osteoarthritis, rheumatoid art hritis, gout, lupus, and ﬁ bromyalgia.
Table: Relative prevalence of somatic and psychiatric comorbidities in people with versus without epilepsy, stratiﬁ ed by study*
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use only validated screening and diagnostic methods to 
minimise the risk of misclassiﬁ cation bias while also 
applying these equally to all participants to minimise 
surveillance bias, ensure a high response rate to minimise 
non-response bias, and ensure that all results are reported 
to minimise the risk of publication bias.
All of the aforementioned studies are cross-sectional 
(ie, a single snapshot in time) and conclusions regarding 
whether the comorbid condition or epilepsy arose ﬁ rst 
are speculative. Some longitudinal studies have been 
conducted and reported bidirectional eﬀ ects between 
epilepsy and several conditions, including depression,50,51 
suicidality,50,51 anxiety,50 psychosis or schizophrenia,52,53 
autism,28 migraine,54 stroke,55,56 and dementia.57,58 Whether 
these associations are truly bidirectional or as a result of 
variable temporal sequence, however, is unclear. Future 
studies, preferably experimental studies that can 
ascertain the causal nature of such associations and the 
direction of the relation, are needed.
Relevance and implications
Screening and diagnosis
One of the more fundamental features of the 
comorbidities of epilepsy is their eﬀ ects on the time of 
detection of the index disease since they might act as an 
iatrotropic stimulus.1 Regular neurological follow-up in 
individuals with a known brain neoplasm, for example, 
will enable earlier detection of a seizure disorder.
Understanding which comorbidities might develop in 
people with epilepsy is equally relevant. A report by the 
US Institute of Medicine emphasised the importance of 
the early identiﬁ cation of comorbid conditions in people 
with epilepsy.28 The idea is that early detection would 
lead to early intervention and tangible health-care 
beneﬁ ts for the patient. Psychiatric, cognitive, and 
several somatic comorbidities (eg, migraine and 
osteoporosis) are frequently undetected and undertreated 
in people with epilepsy.59–62 The Institute of Medicine 
recommended that relevant organisations “establish and 
disseminate a standard screening protocol for people 
with epilepsy that implements screening on a regular 
basis for comorbidities…”.28 Screening instruments and 
guidelines exist for conditions such as osteoporosis and 
depression in the general population; however, these 
methods have not been translated and validated for use 
in people with epilepsy.28 The absence of such 
instruments and guidelines is a clear and pressing gap 
in epilepsy care.
Treatment, prognosis, and quality of life
The presence of comorbid conditions can aﬀ ect 
therapeutic decisions in people with epilepsy. Comorbid 
hepatic disease or renal insuﬃ  ciency, migraine, or 
depression, for example, could be relevant in decisions 
about antiepileptic drugs, while the risk of cognitive 
deﬁ cits might preclude some surgical options—eg, risk 
of severe memory impairment from temporal lobectomy.
Investigation of the potential relation between auto-
immune disease and epilepsy is expanding. One study 
reported a statistically signiﬁ cantly elevated prevalence of 
epilepsy in 135 394 individuals with autoimmune disease 
(ie, type 1 diabetes, psoriasis, rheumatoid arthritis, Graves’ 
disease, Hashimoto’s thyroiditis, Crohn’s disease, 
ulcerative colitis, systemic lupus erythematosus, anti-
phospholipid syndrome, Sjögren’s syndrome, myasthenia 
gravis, and coeliac disease).63 This association has 
potentially important implications for epilepsy treatment 
in some cases, because, for example, individuals with 
epilepsy and anti-GAD antibodies can be successfully 
treated with immunotherapies.64
Increasing evidence shows that treating comorbidities 
might also aﬀ ect the degree of seizure control. An analysis 
of the US Food and Drug Administration data on 
psychotropic drugs, extracted from phase 2 and 3 clinical 
trials with 75 873 participants, showed that those given 
antidepressants were less likely to have an incident 
epileptic seizure.65 Similarly, treatment of the seizures 
could aﬀ ect the comorbidity. The rate of cognitive decline 
seen with some epilepsies, for example, could be slowed 
down or even reversed by epilepsy surgery.66
Comorbid conditions might allow for so-called 
prognostic anticipation,1 in which their presence could 
aﬀ ect, and therefore allow some prediction of, the 
prognosis of the index disease. Comorbidity has been 
associated with increased risk of mortality, functional 
status, quality of life, and diﬀ erent aspects of health care 
in the context of several index diseases.67 For instance, 
migraine was associated with a reduced probability of 
early antiepileptic drug response and seizure freedom.7 
Psychiatric disease was associated with a higher risk of 
pharmaco-resistance68 and worsened outcome after 
anterior temporal lobectomy.69
Comorbid health conditions in children with new-
onset epilepsy have been associated with reduced quality 
of life.70 Intellectual disabilities and conditions such as 
depression and attention deﬁ cit hyperactivity disorder 
have been independently associated with poor social 
adjustment and academic underachievement in children 
with epilepsy, independent of the severity and type of 
epilepsy.71–74 Similar comorbid conditions in adults, 
including depression and anxiety, have been associated 
with reduced quality of life and a higher risk of 
unemployment.6,75
Health-care cost and use
The health-care costs associated with the co-occurrence of 
medical conditions in the general population are 
substantial. An investigation that examined direct health-
care-related costs in a random sample of 1 217 103 Medicare 
beneﬁ ciaries (aged 65 years or older) in the USA reported 
that individuals with at least two chronic conditions 
(deﬁ ned according to their expected persistence or 
recurrence)76 represented 65% of beneﬁ ciaries and 
accounted for 95% of Medicare expenditures.77 An 
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examination of American private insurance claims data 
showed that in people with epilepsy 80% of direct medical 
costs were not related to epilepsy, but were related to the 
treatment of comorbid somatic and psychiatric 
conditions.78 People with epilepsy who have a high 
comorbidity burden are at increased risk of admission to 
hospital and generally incur medical costs almost 
1∙4 times higher than do individuals without such 
comorbidities.79 A study of 824 483 American veterans, 
aged older than 66 years, showed that veterans with new-
onset epilepsy were at signiﬁ cantly greater risk of medical 
admission over a 4-year period than were veterans without 
epilepsy (odds ratio 4∙84, 95% CI 4∙29–5∙46). The ﬁ ve 
most important predictors of medical admission were 
heart attack (4∙74, 2∙72–8∙28), gallbladder disease (3∙90, 
1∙21–12∙58), anaemia (2∙93, 2∙09–4∙10), angina (2∙57, 
1∙57–4∙22), and alcohol dependence (2∙46, 1∙49–4∙08).80
Mortality
Premature mortality in people with epilepsy is 
increasingly a focus of research.81,82 The role of epilepsy-
related causes of death in premature mortality is often 
emphasised,83 but the role of comorbidities should not be 
overlooked. A meta-analysis of unexpected death in 
epilepsy showed that only 4% of deaths in low-risk 
groups of people with epilepsy in high-income countries 
were attributable to sudden unexplained death in 
epilepsy,84 which is generally regarded as the most 
common, single cause of epilepsy-related death.85
Almost all deaths in people with epilepsy are related to 
the comorbidities of epilepsy—particularly neoplasm, 
cardiovascular, or cerebrovascular disease.86,87 Around 
three-quarters of deaths within one year of epilepsy onset 
are directly related to the underlying epilepsy cause in 
individuals with symptomatic epilepsy, rather than 
seizure-related causes.88 Data from the National General 
Practice Study of Epilepsy, a community-based UK study 
with almost 25 years of follow-up, has shown that people 
with epilepsy are more likely than the general population 
to die of malignant neoplasms, ischaemic heart disease, 
cerebrovascular disease, and pneumonia, after controlling 
for the eﬀ ects of age, sex, and calendar year.89 The 
heightened risk of death from neoplasms persisted even 
after excluding cerebral neoplasms, and was postulated to 
be caused by the purported pro-neoplastic eﬀ ect of some 
antiepileptic drugs or an underlying shared genetic 
predisposition.89 A report from Sweden showed that 
individuals with epilepsy and a history of depression or 
substance abuse were at increased risk of death from 
external causes, including suicide and accidental death.90
Future directions
Two major ways in which the investigation of 
comorbidities oﬀ ers opportunities to further our 
understanding of epilepsy relate to the evolving notion of 
epilepsy as a spectrum, or part of a spectrum, and to their 
use as an important instrument in the study of genetics.
We have generally referred to epilepsy as a single, 
implicitly uniform entity, but epilepsy is, in fact, highly 
heterogeneous in terms of its cause, demographics, 
clinical manifestations, treatment, and prognosis. It is 
best understood as a collection of individual disorders 
that share an abnormal tendency to cause epileptic 
seizures, consisting of dozens of epilepsy syndromes.91 
Indeed, epilepsy can be rationally deﬁ ned as a disorder 
characterised not only by epileptic seizures, but also by 
its associated biological, psychological, and social 
conditions.92,93 The comorbidities of epilepsy form the 
core of these associated conditions and contribute to our 
evolving conceptualisation of epilepsy as a spectrum.94,95
Epilepsy can also be regarded as part of a functional 
spectrum of brain conditions characterised by abnormal 
paroxysmal neuronal or glial activity. This predisposition 
towards paroxysmal activity could be deemed a shared 
risk factor. Some such comorbidities are in the 
neurological realm, such as migraine, but others, such as 
depression, fall within psychiatry. The concept of the 
phenotype of epileptic seizures will not disappear, but an 
evolving appreciation of the functional range of 
neurological disease will have a major eﬀ ect on clinical 
interpretation, diagnosis, and treatment.
In terms of the genetics of epilepsy, phenotyping is an 
important technique in the investigation of gene function 
and the identiﬁ cation of harmful mutations. The process 
of phenotyping relies on identifying relevant comorbidities 
in speciﬁ c groups of individuals. Syndromic epilepsies, 
with conspicuous congenital comorbidity proﬁ les, lend 
themselves to genetic investigation; DOORS syndrome, 
for example, is characterised by a combination of 
sensorineural deafness, onychodystrophy, osteodystrophy, 
and intellectual disability with seizures.96 One 
investigation, however, showed that even in individuals 
with sporadic epilepsy initially thought to be non-
syndromic, genetic factors could account for both the 
epilepsy and comorbid somatic or psychiatric conditions, 
some of which might not be evident unless carefully 
considered or sought.97 Irrespective of the potential 
diﬃ  culties, all comorbidities, including even the most 
inconspicuous, should be regarded as part of the 
stratiﬁ cation and phenotyping in cases of epilepsy.
Conclusions
The comorbidities of epilepsy represent a substantial 
burden for people with epilepsy. The clinical and 
scientiﬁ c community should continue to move forward, 
not only to focus on the description of the statistical 
relation between diﬀ erent conditions, but also to 
deconstruct the causal mechanisms for these 
comorbidities, while bearing in mind the risk of 
artifactual comorbidity. Screening instruments and 
guidelines should be developed to help translate the 
knowledge we have acquired into eﬀ ective and 
meaningful clinical interventions. Existing evidence 
shows that the potential beneﬁ t of such endeavours is 
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great. The study of the comorbidities of epilepsy has the 
potential to transform our understanding of epilepsy, as 
research into these comorbid conditions helps to clarify 
the concept of epilepsy as part of a functional spectrum 
and the important role of genetics.
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